Skip to main content
RGNT logo

Regentis Biomaterials Ltd. (RGNT) Stock Price & Analysis

Regentis Biomaterials Ltd. (RGNT) — MoonshotScore 64/100 (Fair band), calculated Nov 18, 2026. Price $0.7186 (-14.42%), as of the Nov 20, 2026 trading session; market cap $5.05M.

Educational signal · not a buy or sell recommendation · How to read this

$0.7186 −$0.1211 (-14.42%) Market Cap $5.05M

Regentis Biomaterials Ltd. · RGNT

Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions. Their lead product, GelrinC, targets painful knee injuries by utilizing a cell-free hydrogel implant to regenerate damaged cartilage.

Price as of Nov 20, 2026

Key Statistics

64 of 100

MoonshotScore v2 · Regentis Biomaterials (RGNT)

Fair
Business Quality n/a Not scored: the profitability, margin and return-on-capital inputs were not available for this company in the latest run.
Financial Safety Fortress (100)
Valuation n/a Not scored: the valuation-multiple and yield inputs were not available for this company in the latest run.
Growth Durability n/a Not scored: the revenue, earnings and cash-flow growth inputs were not available for this company in the latest run.
Momentum Slipping (26)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Too few pillars have data for a confident read — treat the score as provisional. Business Quality: n/a; Financial Safety: Fortress; Valuation: n/a; Growth Durability: n/a; Momentum: Slipping.

Holding back: weak price trend

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RGNT (53 recorded, newest six shown)
RecordedScoreBand
64Fair
64Fair
64Fair
64Fair
64Fair
64Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.7186
Change on the day-14.42%
Market capitalisation$5.05M—
Shares traded on the day122.3K

Price & events

Other perspectives

Council score for Regentis Biomaterials (RGNT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

2-Factor Breakdown

Financial Safety Strong
Momentum Weak

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Negative
ROE Weak
Gross Margin Negative

Read on: Jun 14, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jun 14, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Regentis Biomaterials (RGNT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Regentis Biomaterials Ltd. (RGNT) is the company analyzed here. The market values it at $5.05M.

3 · Financial strengths and risks

What are the financial strengths and risks for Regentis Biomaterials (RGNT)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak price trend. Trailing ratios: current ratio 5.62.

5 · Peer comparison

How does Regentis Biomaterials compare with its peers?

Short answer

Regentis Biomaterials's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Intuitive Surgical, Inc. (ISRG) Named competitor$399.05 Nov 20, 2026$138B94 5-pillar Nov 18, 2026
Regentis Biomaterials (RGNT) — this page$0.7186$5.05M64
Daxor Corporation (DXR) Same industry, near in market value$7.45 Nov 20, 2026$43.5M47 5-pillar Nov 18, 2026
Precision Optics Corporation, Inc. (POCI) Same industry, near in market value$4.07 Nov 19, 2026$44.8M39 5-pillar Nov 18, 2026
Retractable Technologies, Inc. (RVP) Same industry, near in market value$0.56 Nov 20, 2026$16.7M37 5-pillar Nov 18, 2026
Nephros, Inc. (NEPH) Same industry, near in market value$2.61 Nov 20, 2026$28.4M31 5-pillar Nov 18, 2026
Microbot Medical Inc. (MBOT) Same industry, near in market value$0.68 Nov 20, 2026$45.7M30 5-pillar Nov 18, 2026
ACRES Commercial Realty Corp. (ACR) Named competitor$8.40 Nov 19, 2026$113M28 5-pillar Nov 18, 2026
Harvard Bioscience, Inc. (HBIO) Same industry, near in market value$8.66 Nov 20, 2026$39.6M26 5-pillar Nov 18, 2026
Milestone Scientific Inc. (MLSS) Same industry, near in market value$0.24 Nov 20, 2026$21.8M23 5-pillar Nov 18, 2026
Innovative Eyewear, Inc. (LUCY) Same industry, near in market value$0.70 Nov 19, 2026$6.12M21 5-pillar Nov 18, 2026
Femasys Inc. (FEMY) Same industry, near in market value$1.26 Nov 19, 2026$10.9M20 5-pillar Nov 18, 2026
Stereotaxis, Inc. (STXS) Same industry, near in market value$0.94 Nov 20, 2026$95.0M19 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 9, 2026

Transactions
8
Identified insiders
6
Purchases
0
Sales
0
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RGNT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RGNT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Regentis Biomaterials (RGNT)?

Read these with our analysis →

What Investors Ask About Regentis Biomaterials (RGNT)

These answers are editorial: 1 of these 9 answers is drawn from the RGNT research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for RGNT?

RGNT carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions.

Is RGNT a good stock to buy?

Stock Expert AI does not rate RGNT buy, sell or hold. Regentis Biomaterials Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RGNT stock price today?

The last price recorded for Regentis Biomaterials Ltd. (RGNT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for RGNT?

Regentis Biomaterials faces several key risks inherent to the biotechnology and medical device industries. These include the potential for regulatory setbacks or delays in clinical trials, which could impact the timeline for commercializing GelrinC.

What are the key factors to evaluate for RGNT?

Regentis Biomaterials Ltd. (RGNT) holds a MoonshotScore in the moderate range. Focus on GelrinC, a cell-free hydrogel implant, positions the company in the innovative area of tissue regeneration for knee injuries. Not financial advice.

How frequently does RGNT data refresh on this page?

RGNT's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RGNT's recent stock price performance?

Regentis Biomaterials Ltd. (RGNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Gelrin technology platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RGNT overvalued or undervalued right now?

Regentis Biomaterials Ltd. (RGNT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research RGNT before investing?

Before investing in Regentis Biomaterials Ltd. (RGNT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 8 figures on this page — 6 from Financial Modeling Prep (FMP), 1 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.